Ge Long Hui A P P·2025-10-30 10:56Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 215.072 billion RMB for the first nine months of 2025, reflecting a year-on-year growth of 2.60% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 18.164 billion RMB, showing a decline of 0.66% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 196.908 billion RMB, with a year-on-year increase of 2.91% [1] Profit Analysis - The net profit attributable to shareholders for the first nine months of 2025 was 5.147 billion RMB, representing a year-on-year increase of 26.96% [1] - The profit contributions were 1.665 billion RMB from the industrial segment, 2.653 billion RMB from the commercial segment, and 0.324 billion RMB from major associated enterprises [1] - Excluding one-time special gains from accounting changes, the adjusted net profit was 3.979 billion RMB, reflecting a year-on-year decrease of 1.85% [1] Cash Flow and Development - The company maintained a strong operational cash flow with a net inflow of 2.350 billion RMB, indicating high-quality development [1] Industry Recognition - Shanghai Pharmaceuticals ranked among the top ten in the "2024 Annual Top 100 Pharmaceutical Industrial Enterprises by Main Business Revenue" in China [1] - The company achieved an upgrade in its MSCI ESG rating to AA, reflecting its strong performance in environmental, social, and governance aspects [1]